Inducible regulation of Runx2-stimulated osteogenesis

Gene Therapy

Volumn 13, Issue 11, 2006, Pages 873-882

  Gersbach, C A ^a,c   Le Doux, J M ^a,c   Guldberg, R E ^b,c   García, Andres J ^b,c  

^a Emory University   (United States)

^b GEORGIA INSTITUTE OF TECHNOLOGY   (United States)

^c GEORGIA INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

Bone tissue engineering; Ectopic implantation; Inducible gene expression; Orthopedic regeneration; Retrovirus; Tet off

Indexed keywords

ALKALINE PHOSPHATASE; ANHYDROTETRACYCLINE; COLLAGEN; DRINKING WATER; RETROVIRUS VECTOR; TETRACYCLINE; TRANSCRIPTION FACTOR RUNX2;

ANALYSIS OF VARIANCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BONE DEVELOPMENT; BONE MINERALIZATION; CELL CULTURE; CELL DIFFERENTIATION; COMPUTER ASSISTED TOMOGRAPHY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CULTURE MEDIUM; ENZYME ACTIVITY; HISTOPATHOLOGY; IN VIVO STUDY; MALE; MOUSE; MYOBLAST; NONHUMAN; OSTEOBLAST; PRIORITY JOURNAL; PROTEIN EXPRESSION; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

ANIMALS; ANTI-BACTERIAL AGENTS; BONE TRANSPLANTATION; CELLS, CULTURED; CORE BINDING FACTOR ALPHA 1 SUBUNIT; GENE EXPRESSION REGULATION; GENE THERAPY; GENETIC VECTORS; HINDLIMB; MALE; MICE; MICE, INBRED BALB C; OSTEOBLASTS; OSTEOGENESIS; RETROVIRIDAE; TETRACYCLINE; TISSUE ENGINEERING; TOMOGRAPHY, X-RAY COMPUTED; TRANS-ACTIVATORS; TRANSDUCTION, GENETIC;

ANIMALIA;

EID: 33646765799     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/sj.gt.3302725     Document Type: Article

References (61)

1. Bruder SP, Fox BS. Tissue engineering of bone. Cell based strategies. Clin Orthop 1999; 367 (Suppl): S68-S83.
2. Bruder SP, Jaiswal N, Haynesworth SE. Growth kinetics, self-renewal, and the osteogenic potential of purified human mesenchymal stem cells during extensive subcultivation and following cryopreservation. J Cell Biochem 1997; 64: 278-294.
3. Shi S, Gronthos S, Chen S, Reddi A, Counter CM, Robey PG et al. Bone formation by human postnatal bone marrow stromal stem cells is enhanced by telomerase expression. Nat Biotechnol 2002; 20: 587-591.
4. Simonsen JL, Rosada C, Serakinci N, Justesen J, Stenderup K, Rattan SI et al. Telomerase expression extends the proliferative life-span and maintains the osteogenic potential of human bone marrow stromal cells. Nat Biotechnol 2002; 20: 592-596.
5. Mueller SM, Glowacki J. Age-related decline in the osteogenic potential of human bone marrow cells cultured in three-dimensional collagen sponges. J Cell Biochem 2001; 82: 583-590.
6. Lee JY, Musgrave D, Pelinkovic D, Fukushima K, Cummins J, Usas A et al. Effect of bone morphogenetic protein-2-expressing muscle-derived cells on healing of critical-sized bone defects in mice. J Bone Joint Surg Am 2001; 83-A: 1032-1039.
7. Gersbach CA, Byers BA, Pavlath GK, Guldberg RE, Garcia AJ. Runx2/ Cbfa1-genetically engineered skeletal myoblasts mineralize collagen scaffolds in vitro. Biotechnol Bioeng 2004; 88: 369-378.
8. Krebsbach PH, Gu K, Franceschi RT, Rutherford RB. Gene therapy-directed osteogenesis: BMP-7-transduced human fibroblasts form bone in vivo. Hum Gene Ther 2000; 11: 1201-1210.
9. Hirata K, Tsukazaki T, Kadowaki A, Furukawa K, Shibata Y, Moriishi T et al. Transplantation of skin fibroblasts expressing BMP-2 promotes bone repair more effectively than those expressing Runx2. Bone 2003; 32: 502-512.
10. Turgeman G, Pittman DD, Muller R, Kurkalli BG, Zhou S, Pelled G et al. Engineered human mesenchymal stem cells: A novel platform for skeletal cell mediated gene therapy. J Gene Med 2001; 3: 240-251.
11. Cheng SL, Lou J, Wright NM, Lai CF, Avioli LV, Riew KD. In vitro and in vivo induction of bone formation using a recombinant adenoviral vector carrying the human BMP-2 gene. Calcif Tissue Int 2001; 68: 87-94.
12. Abe N, Lee YP, Sato M, Zhang X, Wu J, Mitani K et al. Enhancement of bone repair with a helper-dependent adenoviral transfer of bone morphogenetic protein-2. Biochem Biophys Res Commun 2002; 297: 523-527.
13. Sugiyama O, Orimo H, Suzuki S, Yamashita K, Ito H, Shimada T. Bone formation following transplantation of genetically modified primary bone marrow stromal cells. J Orthop Res 2003; 21: 630-637.
14. Dunn CA, Jin Q, Taba Jr M, Franceschi RT, Bruce RR, Giannobile WV. BMP gene delivery for alveolar bone engineering at dental implant defects. Mol Ther 2005; 11: 294-299.
15. Tsuda H, Wada T, Ito Y, Uchida H, Dehari H, Nakamura K et al. Efficient BMP2 gene transfer and bone formation of mesenchymal stem cells by a fiber-mutant adenoviral vector. Mol Ther 2003; 7: 354-365.
16. Jane Jr JA, Dunford BA, Kron A, Pittman DD, Sasaki T, Li JZ et al. Ectopic osteogenesis using adenoviral bone morphogenetic protein (BMP)-4 and BMP-6 gene transfer. Mol Ther 2002; 6: 464-470.
17. Sugiyama O, An DS, Kung SP, Feeley BT, Gamradt S, Liu NQ et al. Lentivirus-mediated gene transfer induces long-term transgene expression of BMP-2 in vitro and new bone formation in vivo. Mol Ther 2005; 11: 390-398.
18. Zheng H, Guo Z, Ma Q, Jia H, Dang G. Cbfa1/osf2 transduced bone marrow stromal cells facilitate bone formation in vitro and in vivo. Calcif Tissue Int 2004; 74: 194-203.
19. Byers BA, Guldberg RE, Garcia AJ. Synergy between genetic and tissue engineering: Runx2 overexpression and in vitro construct development enhance in vivo mineralization. Tissue Eng 2004; 10: 1757-1766.
20. Zhao Z, Zhao M, Xiao G, Franceschi RT. Gene transfer of the Runx2 transcription factor enhances osteogenic activity of bone marrow stromal cells in vitro and in vivo. Mol Ther 2005; 12: 247-253.
21. Byers BA, Guldberg RE, Hutmacher DW, Garcia AJ. Effects of Runx2 genetic engineering and in vitro maturation of tissue-engineered constructs on the repair of critical size bone defects. J Biomed Mater Res A 2006; 76A: 646-655.
22. Baltzer AW, Lieberman JR. Regional gene therapy to enhance bone repair. Gene Therapy 2004; 11: 344-350.
23. Ide H, Yoshida T, Matsumoto N, Aoki K, Osada Y, Sugimura T et al. Growth regulation of human prostate cancer cells by bone morphogenetic protein-2. Cancer Res 1997; 57: 5022-5027.
24. Pouliot F, Blais A, Labrie C. Overexpression of a dominant negative type II bone morphogenetic protein receptor inhibits the growth of human breast cancer cells. Cancer Res 2003; 63: 277-281.
25. Moutsatsos IK, Turgeman G, Zhou S, Kurkalli BG, Pelled G, Tzur L et al. Exogenously regulated stem cell-mediated gene therapy for bone regeneration. Mol Ther 2001; 3: 449-461.
26. Peng H, Usas A, Hannallah D, Olshanski A, Cooper GM, Huard J. Noggin improves bone healing elicited by muscle stem cells expressing inducible BMP4. Mol Ther 2005; 12: 239-246.
27. Goverdhana S, Puntel M, Xiong W, Zirger JM, Barcia C, Curtin JF et al. Regulatable gene expression systems for gene therapy applications: progress and future challenges. Mol Ther 2005; 12: 189-211.
28. Gossen M, Bujard H. Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc Natl Acad Sci USA 1992; 89: 5547-5551.
29. Gossen M, Freundlieb S, Bender G, Muller G, Hillen W, Bujard H. Transcriptional activation by tetracyclines in mammalian cells. Science 1995; 268: 1766-1769.
30. Mizuguchi H, Hayakawa T. The tet-off system is more effective than the tet-on system for regulating transgene expression in a single adenovirus vector. J Gene Med 2002; 4: 240-247.
31. Gafni Y, Pelled G, Zilberman Y, Turgeman G, Apparailly F, Yotvat H et al. Gene therapy platform for bone regeneration using an exogenously regulated, AAV-2-based gene expression system. Mol Ther 2004; 9: 587-595.
32. Peng H, Usas A, Gearhart B, Young B, Olshanski A, Huard J. Development of a self-inactivating tet-on retroviral vector expressing bone morphogenetic protein 4 to achieve regulated bone formation. Mol Ther 2004; 9: 885-894.
33. Schmitt JM, Hwang K, Winn SR, Hollinger JO. Bone morphogenetic proteins: an update on basic biology and clinical relevance. J Orthop Res 1999; 17: 269-278.
34. Lee KS, Kim HJ, Li QL, Chi XZ, Ueta C, Komori T et al. Runx2 is a common target of transforming growth factor beta1 and bone morphogenetic protein 2, and cooperation between Runx2 and Smad5 induces osteoblast-specific gene expression in the pluripotent mesenchymal precursor cell line C2C12. Mol Cell Biol 2000; 20: 8783-8792.
35. Ducy P, Zhang R, Geoffroy V, Ridall AL, Karsenty G. Osf2/Cbfa1: A transcriptional activator of osteoblast differentiation. Cell 1997; 89: 747-754.
36. Komori T, Yagi H, Nomura S, Yamaguchi A, Sasaki K, Deguchi K et al. Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell 1997; 89: 755-764.
37. Franceschi RT, Yang S, Rutherford RB, Krebsbach PH, Zhao M, Wang D. Gene therapy approaches for bone regeneration. Cells Tissues Organs 2004; 176: 95-108.
38. Byers BA, Pavlath GK, Murphy TJ, Karsenty G, Garcia AJ. Cell-type-dependent up-regulation of in vitro mineralization after overexpression of the osteoblast-specific transcription factor Runx2/ Cbfa1. J. Bone Miner Res 2002; 17: 1931-1944.
39. Byers BA, Garcia AJ. Exogenous Runx2 expression enhances in vitro osteoblastic differentiation and mineralization in primary bone marrow stromal cells. Tissue Eng 2004; 10: 1623-1632.
40. Gersbach CA, Byers BA, Pavlath GK, Garcia AJ. Runx2/Cbfa1 stimulates transdifferentiation of primary skeletal myoblasts into a mineralizing osteoblastic phenotype. Exp Cell Res 2004; 300: 406-417.
41. Murphy TJ, Pavlath GK, Wang X, Boss V, Abbott KL, Robida AM et al. Retroviral vectors applied to gene regulation studies. Methods Enzymol 2002; 345: 539-551.
42. Gossen M, Bujard H. Anhydrotetracycline, a novel effector for tetracycline controlled gene expression systems in eukaryotic cells. Nucl Acids Res 1993; 21: 4411-4412.
43. Cartmell SH, Porter BD, Garcia AJ, Guldberg RE. Effects of medium perfusion rate on cell-seeded three-dimensional bone constructs in vitro. Tissue Eng 2003; 9: 1197-1203.
44. Bonewald LF, Harris SE, Rosser J, Dallas MR, Dallas SL, Camacho NP et al. von Kossa staining alone is not sufficient to confirm that mineralization in vitro represents bone formation. Calcif Tissue Int 2003; 72: 537-547.
45. Franceschi RT. Functional cooperativity between osteoblast transcription factors: Evidence for the importance of subnuclear macromolecular complexes? Calcif Tissue Int 2003; 72: 638-642.
46. Yang S, Wei D, Wang D, Phimphilai M, Krebsbach PH, Franceschi RT. In vitro and in vivo synergistic interactions between the Runx2/Cbfa1 transcription factor and bone morphogenetic protein-2 in stimulating osteoblast differentiation. J Bone Miner Res 2003; 18: 705-715.
47. Urlinger S, Baron U, Thellmann M, Hasan MT, Bujard H, Hillen W. Exploring the sequence space for tetracycline-dependent transcriptional activators: Novel mutations yield expanded range and sensitivity. Proc Natl Acad Sci USA 2000; 97: 7963-7968.
48. Salucci V, Scarito A, Aurisicchio L, Lamartina S, Nicolaus G, Giampaoli S et al. Tight control of gene expression by a helper-dependent adenovirus vector carrying the rtTA2(s)-M2 tetracycline transactivator and repressor system. Gene Therapy 2002; 9: 1415-1421.
49. Hofmann A, Nolan GP, Blau HM. Rapid retroviral delivery of tetracycline-inducible genes in a single autoregulatory cassette. Proc Natl Acad Sci USA 1996; 93: 5185-5190.
50. Emerman M, Temin HM. Genes with promoters in retrovirus vectors can be independently suppressed by an epigenetic mechanism. Cell 1984; 39: 449-467.
51. Baum C, von Kalle C, Staal FJ, Li Z, Fehse B, Schmidt M et al. Chance or necessity? Insertional mutagenesis in gene therapy and its consequences. Mol Ther 2004; 9: 5-13.
52. Koefoed M, Ito H, Gromov K, Reynolds DG, Awad HA, Rubery PT et al. Biological effects of rAAV-caAlk2 coating on structural allograft healing. Mol Ther 2005; 12: 212-218.
53. Ito H, Koefoed M, Tiyapatanaputi P, Gromov K, Goater JJ, Carmouche J et al. Remodeling of cortical bone allografts mediated by adherent rAAV-RANKL and VEGF gene therapy. Nat Med 2005; 11: 291-297.
54. Pola E, Gao W, Zhou Y, Pola R, Lattanzi W, Sfeir C et al. Efficient bone formation by gene transfer of human LIM mineralization protein-3. Gene Therapy 2004; 11: 683-693.
55. Zhao M, Zhao Z, Koh JT, Jin T, Franceschi RT. Combinatorial gene therapy for bone regeneration: Cooperative interactions between adenovirus vectors expressing bone morphogenetic proteins 2, 4, and 7. J Cell Biochem 2005; 95: 1-16.
56. Phillips JE, Gersbach CA, Wojtowicz AM, Garcia AJ. Glucocorticoid-induced osteogenesis is negatively regulated by Runx2/ Cbfa1 serine phosphorylation. J Cell Sci 2006; 119: 581-591.
57. Li JZ, Li H, Hankins GR, Dunford B, Helm GA. Local immunomodulation with CD4 and CD8 antibodies, but not cyclosporine A, improves osteogenesis induced by ADhBMP9 gene therapy. Gene Therapy 2005; 12: 1235-1241.
58. Kaihara S, Bessho K, Okubo Y, Sonobe J, Kawai M, Iizuka T. Simple and effective osteoinductive gene therapy by local injection of a bone morphogenetic protein-2-expressing recombinant adenoviral vector and FK506 mixture in rats. Gene Therapy 2004; 11: 439-447.
59. Rando TA, Blau HM. Primary mouse myoblast purification, characterization, and transplantation for cell-mediated gene therapy. J Cell Biol 1994; 125: 1275-1287.
60. Springer ML, Blau HM. High-efficiency retroviral infection of primary myoblasts. Somat Cell Mol Genet 1997; 23: 203-209.
61. Hildebrand T, Laib A, Muller R, Dequeker J, Ruegsegger P. Direct three-dimensional morphometric analysis of human cancellous bone: microstructural data from spine, femur, iliac crest, and calcaneus. J Bone Miner Res 1999; 14: 1167-1174.